| Description | Murlentamab (GM102) is a humanized anti-AMhRII antibody. Murlentama has potential antitumor activity that induces macrophage-mediated antitumor-dependent cell-mediated cytotoxic effects (ADCC). Murl can stimulate the pro-inflammatory and anti-tumor internal environment by recruiting, collecting and activating T cells. Murlentama exerts antitumor activity by promoting naive macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming. |
| In vivo | 在体内实验中，Murlentamab（20 mg/kg；静脉注射；每周两次；持续4周）在小鼠肝癌患者衍生的异种移植模型(PDX)[2]中抑制肿瘤生长。 |
| Synonyms | 3C23K, GM102 |
| molecular weight | N/A |
| CAS | 2058047-65-5 |
| Storage | store at low temperature | store at -80°C |
| References | 1. Prat M, et al. Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation. Cancers (Basel). 2021 Apr 13;13(8):1845. 2. Barret JM, et al. The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer. Biology (Basel). 2021 Apr 7;10(4):305. |